Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$221.04M$221.04M+45.1% vs Q2 2022 Net Income$74.75M$74.75M+229.5% vs Q2 2022 EPS Diluted$0.56$0.56+250.0% vs Q2 2022 Operating Income$94,458,000+177.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$68,465,000+74.4% Margins · derivedOperating margin42.7%+20.4 pt vs Q2 2022
Net margin33.8%+18.9 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end